Resistance to immune checkpoint blocker drug linked to metabolic imbalance

A metabolic imbalance in some cancer patients following treatment with a checkpoint inhibitor drug, nivolumab, is associated with resistance to the immunotherapy agent and shorter survival, report scientists.